US-based pharma company Abbott Laboratories (Abbott) announced on 16 May 2014 that it was expanding its presence in Latin American and increasing its branded generics portfolio with the acquisition of CFR Pharmaceuticals (CFR).
Abbott expands generics business in Latin America
Home/Pharma News
|
Posted 06/06/2014
0
Post your comment

Abbott will acquire Kalo Pharma Internacional the holding company that indirectly owns approximately 73% of Chile-based CFR and will conduct a public cash tender offer for all of the outstanding shares of CFR. Assuming all publicly-held shares are tendered, the total purchase price would be approximately US$2.9 billion.
CFR is one of the leading branded generics companies in Latin America, with a presence in 15 Latin American markets. The company has more than 1,000 products in the areas of women’s health, central nervous system, cardiovascular and respiratory diseases. The deal will place Abbott among the top 10 pharmaceutical companies in the region, more than doubling Abbott’s Latin American branded generics pharmaceutical presence and further expanding the company’s presence in fast-growing markets.
The Latin American pharmaceutical market is expected to reach US$73 billion in sales during 2014, and is expected to reach US$124 billion by 2018, with estimated annual growth rates of two to three times that of developed markets over the coming years, according to IMS forecasts.
Related article
CFR pharma expands global ambitions with Adcock bid
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.
Source: Abbott, CFR
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment